Jean-Jacques Kiladjian Selected Research

N- (cyanomethyl)- 4- (2- ((4- (4- morpholinyl)phenyl)amino)- 4- pyrimidinyl)benzamide

1/2022	Momelotinib reduces transfusion requirements in patients with myelofibrosis.
4/2021	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
1/2021	Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
2/2018	Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
12/2017	SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean-Jacques Kiladjian Research Topics

Disease

45	Primary Myelofibrosis (Myelosclerosis) 07/2022 - 07/2009
41	Neoplasms (Cancer) 10/2022 - 11/2010
31	Polycythemia Vera 12/2022 - 01/2003
16	Splenomegaly 04/2022 - 02/2011
13	Essential Thrombocythemia 12/2022 - 06/2006
10	Anemia 04/2021 - 02/2002
8	Thrombocytopenia (Thrombopenia) 01/2022 - 03/2012
8	Thrombosis (Thrombus) 12/2021 - 01/2003
7	Polycythemia (Erythrocytosis) 01/2022 - 05/2011
6	Thrombocytosis (Thrombocythemia) 04/2022 - 10/2012
5	Leukemia 03/2022 - 01/2003
5	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2022 - 11/2010
5	Hemorrhage 01/2022 - 01/2017
4	Fibrosis (Cirrhosis) 01/2021 - 05/2009
4	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 03/2008
4	Headache (Headaches) 01/2021 - 01/2016
4	Fatigue 01/2021 - 07/2013
4	Pruritus (Itching) 03/2020 - 07/2013
4	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2011 - 02/2006
3	Inflammation (Inflammations) 04/2021 - 09/2018
2	Leukocytosis (Pleocytosis) 04/2022 - 08/2015
2	Diarrhea 01/2021 - 01/2016
2	Wernicke Encephalopathy (Wernicke's Encephalopathy) 01/2021 - 07/2017
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 12/2020 - 09/2007
2	Infections 04/2018 - 12/2017
2	Sepsis (Septicemia) 02/2018 - 05/2017
2	Peripheral Nervous System Diseases (PNS Diseases) 02/2018 - 12/2017
2	Lymphoma (Lymphomas) 01/2018 - 07/2013
2	Fever (Fevers) 05/2017 - 07/2013
2	Heart Failure 05/2017 - 01/2013
2	Cytopenia 05/2017 - 06/2016
1	Dehydration (Water Stress) 12/2021
1	von Willebrand Diseases (von Willebrand's Disease) 09/2021
1	Hemolysis 01/2021
1	Injection Site Reaction 01/2021
1	Chronic Disease (Chronic Diseases) 01/2021
1	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 01/2021
1	Acute Promyelocytic Leukemia 01/2021

Drug/Important Bio-Agent (IBA)

30	ruxolitinibIBA 01/2022 - 03/2012
13	InterferonsIBA 12/2022 - 09/2006
13	Janus Kinase InhibitorsIBA 07/2022 - 12/2013
11	Hydroxyurea (Hydrea)FDA LinkGeneric 12/2022 - 06/2006
9	Janus KinasesIBA 01/2022 - 03/2012
8	Proteins (Proteins, Gene)FDA Link 10/2022 - 12/2010
8	fedratinibIBA 01/2022 - 07/2017
7	Interferon-alpha (Interferon Alfa)IBA 09/2021 - 10/2008
6	Phosphotransferases (Kinase)IBA 10/2021 - 05/2011
5	N- (cyanomethyl)- 4- (2- ((4- (4- morpholinyl)phenyl)amino)- 4- pyrimidinyl)benzamideIBA 01/2022 - 12/2017
5	Syntex adjuvant formulationIBA 12/2017 - 11/2012
4	Pharmaceutical PreparationsIBA 03/2022 - 02/2011
4	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA 01/2022 - 05/2017
4	Janus Kinase 2IBA 12/2021 - 01/2016
4	CalreticulinIBA 12/2021 - 01/2017
4	anagrelide (Agrylin)FDA LinkGeneric 09/2021 - 02/2014
4	Hemoglobins (Hemoglobin)IBA 04/2021 - 03/2011
4	Janus Kinase 1IBA 01/2018 - 09/2015
3	imetelstatIBA 07/2022 - 10/2021
3	Telomerase (Telomerase Reverse Transcriptase)IBA 07/2022 - 01/2020
3	Erythropoietin FDA Link 01/2022 - 02/2002
3	Pipobroman (Vercyte)FDA Link 10/2011 - 01/2003
2	Biomarkers (Surrogate Marker)IBA 10/2021 - 07/2015
2	IronIBA 04/2021 - 01/2017
2	NF-kappa B (NF-kB)IBA 01/2021 - 02/2006
2	Biological ProductsIBA 12/2020 - 05/2011
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 05/2019 - 12/2018
2	Immunologic Factors (Immunomodulators)IBA 06/2016 - 02/2011
2	HematinicsIBA 01/2015 - 02/2011
2	Reticulin (Reticular Fiber)IBA 01/2012 - 05/2009
2	DNA (Deoxyribonucleic Acid)IBA 01/2012 - 05/2011
2	Dihydrotachysterol (AT 10)IBA 10/2011 - 01/2003
1	siremadlinIBA 03/2022
1	Interleukin-1 Receptor-Associated KinasesIBA 01/2022
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2021
1	CalciumIBA 12/2021
1	Thrombopoietin ReceptorsIBA 12/2021
1	Danazol (Azol)FDA LinkGeneric 04/2021
1	Arsenic Trioxide (Trisenox)FDA Link 01/2021
1	ArsenicIBA 01/2021
1	Complement System Proteins (Complement)IBA 01/2021
1	CytokinesIBA 01/2021
1	Oncogene Proteins (Oncogene Protein)IBA 01/2021
1	eculizumab FDA Link 01/2021
1	Peptides (Polypeptides)IBA 01/2021
1	pomalidomideIBA 01/2021
1	3- (5- amino- 2- methyl- 4- oxoquinazolin- 3(4H)- yl)piperidine- 2,6- dioneIBA 01/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	Thiamine (Aneurin)FDA Link 01/2021
1	pegcetacoplanIBA 01/2021
1	Activin Receptors (Activin Receptor)IBA 12/2020
1	LigandsIBA 12/2020

Therapy/Procedure

47	Therapeutics 12/2022 - 01/2003
5	Drug Therapy (Chemotherapy) 04/2022 - 01/2003
3	Transplantation 01/2021 - 01/2018
3	Erythrocyte Transfusion 02/2018 - 01/2017
2	Splenectomy 01/2021 - 02/2011
2	Drug Tapering 02/2018 - 03/2012
2	Stem Cell Transplantation 01/2018 - 01/2015
1	Hemodilution 01/2021
1	Cell Transplantation 01/2021
1	Complementary Therapies (Alternative Medicine) 12/2020